A Study for Adults With Recurrent IDH1 or IDH2 Mutated Gliomas
National Cancer Institute researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.
What the study involves:
- Full physical and neurological examination
- Health and symptoms questionnaire
- MRIs and laboratory tests
- Study of tumor tissue from prior surgeries
- Receive drug nivolumab for up to 20 treatments over 64 weeks
- Your samples used for genetic and biomarker testing
- Monitoring calls every six months after treatment
- Visits every month during treatment and 28, 60, 100 days after treatment
- All tests, procedures and medications provided at no cost
You can participate if you:
- Are age 18 or older
- Are diagnosed with a glioma with IDH1or IDH2 mutation that has returned
- Do not have hepatitis
- Are not pregnant or breastfeeding
The NIH Clinical Center, America's Research Hospital located in Bethesda, MD, Metro red line (Medical Center stop).
For more information:
NIH Clinical Center
Office of Patient Recruitment
800-411-1222 (refer to study 19-C-0006)
(TTY users dial 7-1-1)
Se habla español
Email: ccopr@nih.gov
Or go online:
https://go.usa.gov/x7rmn
Department of Health and Human Services
National Institutes of Health Clinical Center
National Cancer Institute